These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 15625049)
1. [A word of warning about economic evaluations]. de SolĂ -Morales O; Pons JM Gac Sanit; 2004; 18(6):486; author reply 487-8. PubMed ID: 15625049 [No Abstract] [Full Text] [Related]
2. A price for cost-effectiveness: implications for recombinant human activated protein C (rhAPC). Chalfin DB; Teres D; Rapoport J Crit Care Med; 2003 Jan; 31(1):306-8. PubMed ID: 12545034 [No Abstract] [Full Text] [Related]
3. Evidence-based disease management in medication-use evaluation: application to drotrecogin alfa (activated) in severe sepsis. Durthaler JM; Ernst FR Am J Health Syst Pharm; 2006 Aug; 63(15):1453-60. PubMed ID: 16849712 [No Abstract] [Full Text] [Related]
4. Long-term cost effectiveness of drotrecogin alfa (activated): an unanswered question. Banks SM; Gerstenberger E; Eichacker PQ; Natanson C Crit Care Med; 2003 Jan; 31(1):308-9. PubMed ID: 12545035 [No Abstract] [Full Text] [Related]
5. Appraisal of treatment for severe sepsis in intensive care units. Burchell M; Ruiz F; Barnett D Ann R Coll Surg Engl; 2005 Jul; 87(4):283-4. PubMed ID: 16888847 [No Abstract] [Full Text] [Related]
6. Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated). McEvoy M Am J Crit Care; 2003 Sep; 12(5):398; author reply 398. PubMed ID: 14503421 [No Abstract] [Full Text] [Related]
7. Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated). Morris PE Am J Crit Care; 2003 Mar; 12(2):94-7. PubMed ID: 12625165 [No Abstract] [Full Text] [Related]
8. Drotrecogin alfa (activated) for severe sepsis. Drug Ther Bull; 2006 Jan; 44(1):5-8. PubMed ID: 16425899 [TBL] [Abstract][Full Text] [Related]
9. Managing high-cost biotechnology products. Wong DH; Yang P Am J Health Syst Pharm; 2003 Jun; 60(12):1213-6. PubMed ID: 12845915 [No Abstract] [Full Text] [Related]
10. Drotrecogin alfa (activated) in South African private hospital ICUs. Hodgson RE; Williams PG; Foden AP; Grolman D S Afr Med J; 2003 Jul; 93(7):474-5. PubMed ID: 12939910 [No Abstract] [Full Text] [Related]
11. [Medical-economic evaluation of severe sepsis]. Guidet B Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():28-30. PubMed ID: 15359937 [No Abstract] [Full Text] [Related]
12. Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis. Frampton JE; Foster RH Pharmacoeconomics; 2004; 22(7):445-76. PubMed ID: 15137883 [TBL] [Abstract][Full Text] [Related]
13. High-cost sepsis drug forces pharmacists to weigh patients' future. Thompson CA Am J Health Syst Pharm; 2002 Apr; 59(8):692, 697. PubMed ID: 11977851 [No Abstract] [Full Text] [Related]